A Study of the Changes of Breast Uptakein Menstrual Cycle on 18F-FDG PET/CT
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
18F-FDG PET/CT has been known a useful modality to diagnose high-glucose-using cells such as cancer cells by glucose metabolism of FDG. Mainly, FDG takes on cancer and inflammatory cells; however, there have been FDG uptakes on normal tissues by individual physiological characteristics, occasionally. Especially, in fertile fe-males, unusual FDG uptake of breast changes as the menstrual cycle, and disturb diagnosis. Therefore, the study aimed to evaluate the change of breast FDG uptake in menstrual cycle on 18F-FDG PET/CT. 160 females (34±3.5 years old) who do not undergo a gynecologic anamnesis and have regular menstrual cycle over the previous 6 months were examined. They were divided 4 groups (each 40 patients) as flow phase, proliferative phase, ov-ulatory phase and secretory phase using Pregnancy Calculator 0.14. and history taking. Discovery Ste (GE Healthcare, Milwaukee, Mi, USA) was used as PET/CT. We analyzed SUVs on accumulated region on breast, and 3 nuclear medicine specialists did the Blind test. SUVs on the Breast were flow phase (1.64±0.25), proliferative phase (0.93±0.28), ovulatory phase (1.66±0.26) and secretory phase (1.77±0.28). It showed high uptake value in secretory, flow phase and ovulatory phase (p<0.05). In gross analysis, the accumulation of breast was divided in-to 3 grades as comparing with lung and liver. The breast’s uptake was equal to lung (Grade Ⅰ); between lung and liver (Grade II); equal to or greater than liver (Grade III). The results showed high uptake value in secre-tory, flow phase and ovulatory phase (p<0.05). In fertile females, FDG uptake of breast changed as menstrual cycle, and it available to diagnose breast disease. Therefore, we consider reducing false-negative finding of breast disease, by doing examination on appropriate period through history taking about individual menstrual cycle.
Abstract
18F-FDG PET/CT has been known a useful modality to diagnose high-glucose-using cells such as cancer cells by glucose metabolism of FDG. Mainly, FDG takes on cancer and inflammatory cells; however, there have been FDG uptakes on normal tissues by individual physiological characteristics, occasionally. Especially, in fertile fe-males, unusual FDG uptake of breast changes as the menstrual cycle, and disturb diagnosis. Therefore, the study aimed to evaluate the change of breast FDG uptake in menstrual cycle on 18F-FDG PET/CT. 160 females (34±3.5 years old) who do not undergo a gynecologic anamnesis and have regular menstrual cycle over the previous 6 months were examined. They were divided 4 groups (each 40 patients) as flow phase, proliferative phase, ov-ulatory phase and secretory phase using Pregnancy Calculator 0.14. and history taking. Discovery Ste (GE Healthcare, Milwaukee, Mi, USA) was used as PET/CT. We analyzed SUVs on accumulated region on breast, and 3 nuclear medicine specialists did the Blind test. SUVs on the Breast were flow phase (1.64±0.25), proliferative phase (0.93±0.28), ovulatory phase (1.66±0.26) and secretory phase (1.77±0.28). It showed high uptake value in secretory, flow phase and ovulatory phase (p<0.05). In gross analysis, the accumulation of breast was divided in-to 3 grades as comparing with lung and liver. The breast’s uptake was equal to lung (Grade Ⅰ); between lung and liver (Grade II); equal to or greater than liver (Grade III). The results showed high uptake value in secre-tory, flow phase and ovulatory phase (p<0.05). In fertile females, FDG uptake of breast changed as menstrual cycle, and it available to diagnose breast disease. Therefore, we consider reducing false-negative finding of breast disease, by doing examination on appropriate period through history taking about individual menstrual cycle.
참고문헌 (16)
- Engel H, "Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations", J Nucl Med, 37, pp.441~446 (1996)
- Strauss LG, "Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients", Eur J Nucl Med, 23, pp.1409~1415 (1996)
- Cook GJ, "Normal physio-logical and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission to-mography scanning: potential for error in interpretation", Semin Nucl Med, 26, pp.308~314 (1996)
- Shreve PD, "Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants", Radiographics, 19, pp.61~77 (1999)
- Cook GJ, "Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11methionine", Eur J Nucl Med Mol Imaging, 26, pp.1363~1378 (1999)
- Blodgett TM, "Combined PET-CT in the head and neck: part 1—physiologic, altered physiologic, and artifactual FDG uptake", Radiographics, 25, pp.897~912 (2005)
- Prabhakar HB, "Blake MA, Bowel hot spots at PET-CT", Radiographics, 27, pp.145~159 (2007)
- Mijin Yun, "Physiologic 18F-FDGUptake in the FallopianTubes at Mid Cycle on PET", CT, 2010, pp.51, 682~685
- Treloar, A. E, "Variations of the Human Menstrual Cycle through Reproductive Life", International Journal of Fertility, 9, pp.77~126 (1967)
- Zangheri B, "PET", CT and breast cancer, 2004, pp.31(suppl 1), 135~142
- Tatsumi M, "Initial experience with FDG-PET", CT in the evaluation of breast cancer, 2006, pp.33, 254~262
- Radan L, "The role of FDG-PET", CT in suspected recurrence of breast cancer, 2006, pp.107, 2545~2551
- Beresford M, "Serial integrated 18F fluorodeox-ythymidine PET", CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma, 2007, pp.13, 424~425
- Rosenberg RD, "Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammo-graphic sensitivity and cancer stage at diagnosis:review of 183,134 screening mammograms in Albuquerque, New Mexico", Radiology, 209, pp.511~ (1998)
- Kerlikowske K, "Effect of age, breast density, and family history on the sensitivity of first screening mammography", JAMA, 276, pp.33~38 (1996)
- Kavanagh AM, "Hormone replacement therapy, percent mammo-graphic density, and sensitivity of mammography", Cancer Epidemiol Biomarkers Prev, 14, pp.1060~1064 (2005)